Dermatomyositis induced by drug therapy: A review of case reports - 24/04/13
, Alice B. Gottlieb, MD, PhD
Reprint requests: Anne M. Seidler, MD, MBA, c/o Alice B. Gottlieb, MD, PhD, Department of Dermatology, Tufts University School of Medicine and Tufts Medical Center, 800 Washington St, Box 114, Boston, MA 02111-1533.Abstract |
Background |
Drugs have occasionally been implicated in dermatomyositis (DM) onset.
Objective |
We sought to review case reports of drug-induced DM.
Methods |
Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined.
Results |
In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug.
Limitations |
Case reports may emphasize unusual findings.
Conclusions |
Further work is needed to differentiate drug effects from underlying, predisposing factors.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ANA, CML, DM, PM
Plan
| Supported by a generous grant from Ms Joan Fabry. |
|
| Disclosure: Dr Seidler received a research/educational grant from Stiefel. Dr Gottlieb (all income paid to employer directly) is a member of the speaker’s bureaus of Amgen Inc and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott Labs, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Medacorp, DermiPsor, Can-Fite, and Incyte; and has research/educational grants from Centocor, Amgen, Wyeth, Immune Control, Abbott, Pharmacare, Incyte, Celgene, and Roche. |
Vol 59 - N° 5
P. 872-880 - novembre 2008 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?